Tessie Che, chairperson & GM of Amaran Biotech shares the story of how she came to lead the company and set its course to become a leading specialty biopharma CMO that leverages high-quality products and best manufacturing practices above all else. As a veteran in the life sciences and pharma industries, Che also shares her insights on the major trends shaping biopharma in Taiwan and internationally. Finally, Che concludes with a message about Amaran’s ambitions to set the gold standard for Taiwanese drug production.
Amaran Biotechnology, Inc. has been awarded cGMP certification from the Taiwan Food and Drug Administration (TFDA). The certificate demonstrates that Amaran Biotechnology manufactures and maintains a level of compliance in accordance with the Pharmaceutical Inspection Convention/Co-Operation Scheme (PIC/s) Guide to Good Manufacturing Practice (GMP). Its scope covers the manufacture of active pharmaceutical ingredients (API) at Amaran’s manufacturing facility, which is located in Hsinchu Biomedical Science Park.
Amaran Biotechnology, Inc., a biopharmaceuticals manufacturer and leading manufacturer of a key protein utilized in immunotherapy development pipelines Stellar Biotechnologies, Inc. (Nasdaq: SBOT), have entered into an exclusive multi-year supply agreement in connection with clinical development studies of immunotherapies for metastatic breast cancer and other cancers.